AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 276: E376-E383, 1999;
0193-1849/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinreb, M.
Right arrow Articles by Shir, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinreb, M.
Right arrow Articles by Shir, N.
Vol. 276, Issue 2, E376-E383, February 1999

The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype

M. Weinreb, A. Grosskopf, and N. Shir

Department of Oral Biology, Goldschleger School of Dental Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

Prostaglandin E2 (PGE2) is an anabolic agent in vivo that stimulates bone formation by recruiting osteoblasts from bone marrow precursors. To understand which of the known PGE2 receptors (EP1-4) is involved in this process, we tested the effect of PGE2 and various EP agonists and/or antagonists on osteoblastic differentiation in cultures of bone marrow cells by counting bone nodules and measuring alkaline phosphatase activity. PGE2 increased both parameters, peaking at 100 nM, an effect that was mimicked by forskolin and was abolished by 2',3'-dideoxyadenosine (an adenylate cyclase inhibitor) and was thus cAMP dependent, pointing to the involvement of EP2 or EP4. Consistently, 17-phenyl-omega -trinor PGE2 (EP1 agonist) and sulprostone (EP3/EP1 agonist) lacked any anabolic activity. Furthermore, butaprost (EP2 agonist) was inactive, 11-deoxy-PGE1 (EP4/EP2 agonist) was as effective as PGE2, and the PGE2 effect was abolished dose dependently by the selective EP4 antagonist AH-23848B, suggesting the involvement of EP4. We also found that PGE2 increased nodule formation and AP activity when added for the initial attachment period of 24 h only. Thus this study shows that PGE2 stimulates osteoblastic differentiation in bone marrow cultures, probably by activating the EP4 receptor, and that this effect may involve recruitment of noncommitted (nonadherent) osteogenic precursors, in agreement with its suggested mode of operation in vivo.

prostanoid receptors; osteoblast recruitment; bone nodules


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
F. Okamoto, H. Kajiya, H. Fukushima, E. Jimi, and K. Okabe
Prostaglandin E2 activates outwardly rectifying Cl- channels via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts
Am J Physiol Cell Physiol, July 1, 2004; 287(1): C114 - C124.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. J. Minguell, A. Erices, and P. Conget
Mesenchymal Stem Cells
Experimental Biology and Medicine, June 1, 2001; 226(6): 507 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. D. Breyer and R. M. Breyer
Prostaglandin E receptors and the kidney
Am J Physiol Renal Physiol, July 1, 2000; 279(1): F12 - F23.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
T. Sanchez and J. J. Moreno
Role of EP1 and EP4 PGE2 subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation
Am J Physiol Cell Physiol, February 1, 2002; 282(2): C280 - C288.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online